Cpt1a - carnitine palmitoyltransferase 1a, liver Gene

Also Known as CPTI; Cpt1; C730027G07

Species: Mus musculus

Gene Type: protein coding
Gene ID: 12894

Summary

Enables carnitine O-palmitoyltransferase activity and palmitoleoyltransferase activity. Predicted to be involved in several processes, including carnitine metabolic process; positive regulation of fatty acid beta-oxidation; and regulation of Insulin secretion. Predicted to act upstream of or within lipid metabolic process. Located in mitochondrial inner membrane. Is expressed in several structures, including alimentary system; central nervous system; integumental system; sensory organ; and urinary system. Used to study carnitine palmitoyltransferase I deficiency. Human ortholog(s) of this gene implicated in carnitine palmitoyltransferase I deficiency and lipid metabolism disorder. Orthologous to human CPT1A (carnitine palmitoyltransferase 1A). [provided by Alliance of Genome Resources, Apr 2022]

Cpt1a Products (1)

mRNA Protein Name
NM_013495.2 NP_038523.2 carnitine O-palmitoyltransferase 1, liver isoform

Gene Ontology

  • Molecular Function
Molecular Function GO Annotation Evidence References Source
enables carnitine O-palmitoyltransferase activity IDA
IDA: Inferred from direct assay
12920182 MGI
enables carnitine O-palmitoyltransferase activity IMP
IMP: Inferred from mutant phenotype
16169268 MGI
enables protein binding IPI
IPI: Inferred from physical interaction
16271724 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

carnitine O-palmitoyltransferase 1, liver isoform

  • CPT I

  • CPT1-L

  • CPTI-L

  • L-CPT I

  • carnitine palmitoyltransferase 1, liver

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Phase
HY-115938 BEC2 Activator 98.0% Phase 3
HY-168046 ALG-055009 Agonist 95.32% Phase 2

Pre-clinical Phase

Bioactive Molecules (18)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-50202 Etomoxir 99.58% Yes
HY-12364 C75 99.91% Unkown
HY-50202A Etomoxir sodium salt 99.79% Yes
HY-N2593 Isorhapontigenin 99.82% Unkown
HY-N0723 Neomangiferin 99.80% Unkown
HY-50670 DGAT-1 inhibitor 2 95.33% Unkown
HY-RS03122 CPT1A Human Pre-designed siRNA Set A / Unkown
HY-W588256 12-Tridecenoic acid Activator 95.0% Unkown
HY-W420033 (S)-(+)-Etomoxir 98.65% Unkown
HY-161027 2,6-Didehydropeperomin B / Unkown
HY-N8144 Niga-ichigoside F1 99.0% Unkown
HY-N9333 Wistin Agonist 97.63% Unkown
HY-50202R Etomoxir (Standard) 99.56% Unkown
HY-RS16248 Cpt1a Mouse Pre-designed siRNA Set A / Unkown
HY-12364B (−)-C75 / Unkown
HY-183318 PPARα/δ agonist 4 Agonist / Unkown
HY-116257 GSK-7227 Agonist 98.03% Unkown
HY-RS23138 Cpt1a Rat Pre-designed siRNA Set A / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cpt1a NCBI NCBI:1374